|
1
|
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).
|
Lancet Oncol
|
2008
|
5.50
|
|
2
|
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.
|
Blood
|
2007
|
5.18
|
|
3
|
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.
|
Blood
|
2005
|
5.08
|
|
4
|
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
|
J Clin Oncol
|
2005
|
3.61
|
|
5
|
Improvement of overall survival in advanced stage mantle cell lymphoma.
|
J Clin Oncol
|
2008
|
3.44
|
|
6
|
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.
|
Blood
|
2004
|
3.04
|
|
7
|
Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation.
|
J Clin Oncol
|
2013
|
2.95
|
|
8
|
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.
|
Blood
|
2004
|
2.84
|
|
9
|
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).
|
Blood
|
2006
|
2.83
|
|
10
|
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.
|
Blood
|
2004
|
2.50
|
|
11
|
Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma.
|
J Clin Oncol
|
2002
|
2.23
|
|
12
|
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.
|
Br J Haematol
|
2007
|
2.09
|
|
13
|
Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.
|
Blood
|
2010
|
1.94
|
|
14
|
The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL.
|
Blood
|
2012
|
1.58
|
|
15
|
Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation.
|
J Clin Oncol
|
2012
|
1.43
|
|
16
|
Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group.
|
Blood
|
2004
|
1.41
|
|
17
|
Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma.
|
J Clin Oncol
|
2010
|
1.39
|
|
18
|
Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas.
|
Haematologica
|
2012
|
1.30
|
|
19
|
High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
|
J Clin Oncol
|
2008
|
1.28
|
|
20
|
Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group.
|
J Clin Oncol
|
2007
|
1.22
|
|
21
|
Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial.
|
Lancet
|
2005
|
1.03
|
|
22
|
Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer.
|
J Clin Oncol
|
2006
|
0.89
|
|
23
|
Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
|
J Clin Oncol
|
2007
|
0.83
|
|
24
|
Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
|
Cancer
|
2006
|
0.80
|
|
25
|
Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy.
|
Blood
|
2010
|
0.75
|
|
26
|
Granulocyte-colony stimulating factor response is superior to neutropenia duration in predicting the risk of infection after high-dose chemotherapy for myeloma and lymphoma.
|
Leuk Lymphoma
|
2014
|
0.75
|